Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors

Summary

VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This Phase I study will be conducted in HSV-seropositive subjects with advanced malignant solid tumors that are refractory to conventional therapies. This is an open label study to determine the safety and tolerability of VG161, and recommended dose of VG161 for Phase II trials.

Timeline

Start

2021-04-14

Primary completion

2022-03-14

Completion

2022-12-01

Drugs

Indications